[1]李杨,佟铸,谷涌泉.股浅动脉支架内再狭窄的危险因素研究进展[J].介入放射学杂志,2016,(06):554-558.
　LI Yang,TONG Zhu,GU Yong-quan.Risk factors for superficial femoral artery in-stent restenosis: recent progress in research [J].journal interventional radiology,2016,(06):554-558.
点击复制

股浅动脉支架内再狭窄的危险因素研究进展 ()

PDF下载中关闭

  1. 1
  2. 2
  3. 3
分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年06期
页码:
554-558
栏目:
综述
出版日期:
2016-06-25

文章信息/Info

Title:
Risk factors for superficial femoral artery in-stent restenosis: recent progress in research

作者:
李杨; 佟铸; 谷涌泉
Author(s):
LI Yang;  TONG Zhu;  GU Yong-quan
Department of Vascular Surgery, Xuanwu Hospital of Capital Medical University, Vascular Surgery Institute of Capital Medical University, Department of Vascular Surgery of Capital Medical University, Beijing 100053, China
关键词:
【关键词】股浅动脉;  支架内再狭窄;  危险因素
文献标志码:
A
摘要:
【摘要】股浅动脉（SFA）支架植入血管成形术是针对SFA狭窄或闭塞性病变的腔内常用治疗方法,但支架植入术后股浅动脉支架内再狭窄（superficial femoral artery in-stent restenosis,SFA-ISR）的发生率很高,由于大多数的患者直到出现严重临床症状才会再次寻求诊治,所以对于控制支架内再狭窄（ISR）相关危险因素至关重要。近年对SFA-ISR的危险因素研究不断深入,本文就其解剖学特点、病理生理学基础、危险因素研究进展作一综述。


参考文献/References:

［1］Schillinger M, Sabeti S, Dick P, et al.Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting［J］. Circulation, 2007, 115: 2745-2749.

［2］Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery［J］. N Engl J Med, 2006, 354: 1879-1888.

［3］Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial［J］. Circ Cardiovasc Interv, 2010, 3: 267-276.

［4］Qi YX, Qu MJ, Long DK, et al. Rho-GDP dissociation inhibitor alpha downregulated by low shear stress promotes vascular smooth muscle cell migration and apoptosis: a proteomic analysis［J］. Cardiovasc Res, 2008, 80: 114-122.

［5］Herisson F, Heymann MF, Chetiveaux MA, et al. Carotid and femoral atherosclerotic plaques show different morphology［J］. Atherosclerosis, 2011, 216: 348-354.

［6］Campbell JH, Campbell GR. Smooth muscle phenotypic modulation： a personal experience［J］. Arterioscler Thromb Vasc Biol, 2012, 32: 1784-1789.

［7］潘春仰, 邱建平, 陆 林, 等. 冠状动脉介入治疗后支架内再狭窄相关因素［J］. 介入放射学杂志, 2015, 24： 467-471.

［8］Kasaoka S, Tobis JM, Akiyama T, et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis［J］. J Am Coll Cardiol, 1998, 32: 1630-1635.

［9］Bakken AM, Palchik E, Hart JP, et al. Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions［J］. J Vasc Surg, 2007, 46: 946-958.

［10］Gary T, Rief P, Stojakovic T, et al. Lipoproteins and the development of restenosis after stent implantation in the superficial femoral artery in patients with peripheral artery disease［J］. Cardiovasc Intervent Radiol, 2011, 34: 739-743.

［11］Singh M, Gersh BJ, McClelland RL, et al. Predictive factors for ischemic target vessel revascularization in the prevention of restenosis with tranilast and its outcomes (PRESTO) trial［J］. J Am Coll Cardiol, 2005, 45: 198-203.

［12］Iida O, Nanto S, Uematsu M, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions［J］. J Vasc Surg, 2008, 48: 144-149.

［13］Soga Y, Yokoi H, Kawasaki TA, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication［J］. J Am Coll Cardiol, 2009, 53: 48-53.

［14］Soga Y, Iida O, Hirano K, et al. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol［J］. Catheter Cardiovasc Interv, 2012, 79: 541-548.

［15］Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial［J］. Lancet, 2002, 360: 427-435.

［16］Fu SJ, Zhao HG, Shi JT, et al. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses［J］. BMC Genomics, 2008, 9: 369.

［17］Shuvalova YA, Kaminnyi AI, Meshkov AN, et al. Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis［J］. Mol Cell Biochem, 2012, 370: 241-249.

［18］Yilmaz S, Sindel T, Luleci E. Subintimal versus intraluminal recanalization of chronic iliac occlusions［J］. J Endovasc Ther, 2004, 11: 107-118.

［19］Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY Ⅰ study［J］. J Endovasc Ther, 2009, 16: 261-269.

［20］Krankenberg H, Schlueter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST)［J］. Circulation, 2007, 116: 285-292.

［21］Shammas NW, Shammas G, Bryan D, et al. Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions［J］. J Invasive Cardiol, 2009, 21: 266-269.

［22］Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein［J］. N Engl J Med, 2008, 359: 2195-2207.

［23］Ward MR, Tsao PS, Agrotis A, et al. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration［J］. Arterioscler Thromb Vasc Biol, 2001, 21: 208-213.

［24］Amann-Vesti BR, Kozerke S, Krieger E, et al. High wall shear stress measured by magnetic resonance is a predictor of restenosis in the femoral-artery after balloon angioplasty［J］. Int Angiol, 2004, 23: 270-275.

［25］Biancari F, Alback A, Ihlberg L, et al. Angiographic runoff score as a predictor of outcome following femorocrural bypass surgery［J］. Eur J Vasc Endovasc Surg, 1999, 17: 480-485.

［26］Davies MG, Saad WE, Peden EK, et al. Percutaneous superficial femoral artery interventions forclaudication-does runoff matter?［J］. Ann Vasc Surg, 2008, 22: 790-798.

［27］Scheinert D, Grummt L, Piorkowski M, et al. A novelself-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry［J］. J Endovasc Ther, 2011, 18: 745-752.

［28］Garcia L, Jaff MR, Metzger CA, et al. Wire-Interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteriestwelve-month results of the SUPERB trial［J］. Circ Cardiovasc Interv, 2015, 8: 1-8.

［29］Hartung O, Otero A, Dubuc M, et al. Efficacy of hemobahn (R) in the treatment of superficial femoral artery lesions in patients with acute or critical ischemia: a comparative study with claudicants［J］. Eur J Vasc Endovasc Surg, 2005, 30: 300-306.

［30］Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versusbare-metal stents in long SFA lesions: the VIASTAR trial［J］. Cardiovasc Intervent Radiol, 2015, 38: 25-32.

［31］Geraghty PJ, Mewissen MW, Jaff MR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease［J］. J Vasc Surg, 2013, 58: 386-395.

［32］Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results［J］. Circ Cardiovasc Interv, 2011, 4: 495-504.

［33］Bosiers M, Peeters P, Tessarek J, et al. The Zilver PTX single arm study: 12-month results from the TASC C/D lesion subgroup［J］. J Cardiovasc Surg (Torino), 2013, 54: 115-122.

［34］Jaff M, Dake M, Pornpa J, et al. Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices［J］. Catheter Cardiovasc Interv, 2007, 70: 460-462.

［35］Adlakha S, Sheikh M, Wu J, et al. Stent fracture in the coronary and peripheral arteries［J］. J Interv Cardiol, 2010, 23: 411-419.

［36］Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting［J］. J Am Coll Cardiol, 2005, 45: 312-315.

［37］Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis afterfemoropopliteal stenting［J］. J Am Coll Cardiol, 2012, 59: 16-23.

［38］Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting-the dark sides: in-stent restenosis, clinical deterioration, and stent fractures［J］. J Endovasc Ther, 2005, 12: 676-684.

［39］Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results［J］. Circulation, 2002, 106: 1505-1509.

 

相似文献/References:

[1]郑辉,郭富强.Rho/Rho激酶信号通路与支架内再狭窄的研究[J].介入放射学杂志,2012,(02):172.
　ZHENG Hui,GUO Fu-qiang..Studies on Rho/Rho-kinase signalling pathways and in-stent restenosis[J].journal interventional radiology,2012,(06):172.
[2]岑锦明,熊卿圆,杨希立,等. 糖化血红蛋白与冠状动脉支架术后再狭窄的关系[J].介入放射学杂志,2012,(09):725.
　CEN Jin- ming,XIONG Qing- yuan,YANG Xi- li,et al. Relationship between glycated hemoglobin and restenosis after percutaneous coronary intervention procedure[J].journal interventional radiology,2012,(06):725.
[3]王海瑞,潘 涛,畅智慧,等.股腘动脉闭塞支架植入术后支架内再狭窄危险因素——贫血 [J].介入放射学杂志,2016,(11):1007.
　WANG Hai- rui,PAN Tao,CHANG Zhi- hui,et al.Anemia： a risk factor of in- stent restenosis after stenting for femoropopliteal artery occlusion[J].journal interventional radiology,2016,(06):1007.
[4]丁海霞,王富军,马红芳,等.脐带血干细胞移植对兔糖尿病后肢血管病变介入术后支架内再狭窄的影响[J].介入放射学杂志,2016,(08):695.
　DING Hai-xia,WANG Fu-jun,MA Hong-fang,et al.The effect of umbilical cord blood stem cell transplantation on the in-stent restenosis after intervention therapy for diabetic vascular diseases in experimental rabbits [J].journal interventional radiology,2016,(06):695.
[5]刘 蓉,马士新,赵 钢,等.紫杉醇药物涂层球囊扩张冠状动脉支架内再狭窄病变增加远期管腔面积 [J].介入放射学杂志,2017,(04):367.
　LIU Rong,MA Shixing,ZHAO Gang,et al.Long- term lumen area enlarged in coronary in- stent restenosis after the treatment of paclitaxel drug - coated balloon dilatation[J].journal interventional radiology,2017,(06):367.
[6]段润丹,谢 辉,吕 磊,等.股腘动脉支架断裂与支架内再狭窄相关性分析 [J].介入放射学杂志,2017,(06):496.
　DUAN Rundan,XIE Hui,Lv Lei,et al.The correlation between femoral popliteal artery stent fracture and in- stent restenosis[J].journal interventional radiology,2017,(06):496.
[7]解旭品,方 欣,黄昌拼,等.紫杉醇药物涂层球囊治疗股腘动脉支架内再狭窄18例 [J].介入放射学杂志,2017,(06):544.
　XIE Xupin,FANG Xin,HUANG Changpin,et al.Drug- coated balloon with paclitaxel for in- stent restenosis of femoral popliteal artery： initial experience in 18 patients[J].journal interventional radiology,2017,(06):544.
[8]曾书燚,王正东,陈 坚,等.药物洗脱球囊与药物洗脱支架治疗支架内再狭窄疗效比较 [J].介入放射学杂志,2017,(09):839.
　ZENG Shuyi,WANG Zhengdong,CHEN Jian,et al.Paclitaxel- eluting balloon versus drug- eluting stent for in- stent restenosis： comparative study of curative effect[J].journal interventional radiology,2017,(06):839.
[9]钟继明,黄学成,张景昌,等.冠状动脉雷帕霉素涂层支架植入术后支架内再狭窄临床预测因素探讨 [J].介入放射学杂志,2017,(10):874.
　ZHONG Jiming,HUANG Xuecheng,ZHANG Jingchang,et al.Investigation of the clinical predictors of in- stent restenosis after rapamycin- eluting coronary stent implantation[J].journal interventional radiology,2017,(06):874.
[10]刘晓哲,王 兵,刘俊超,等.药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用 [J].介入放射学杂志,2018,27(05):410.
　LIU Xiaozhe,WANG Bing,LIU Junchao,et al.Application of drug- coated balloon in treating femoropopliteal in- stent restenosis[J].journal interventional radiology,2018,27(06):410.

备注/Memo

备注/Memo:
（收稿日期：2015-11-16）


（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-06-21